{"created":"2023-06-20T15:50:32.775346+00:00","id":3355,"links":{},"metadata":{"_buckets":{"deposit":"a13b598d-4eaf-4f04-bc75-049c340186ad"},"_deposit":{"created_by":18,"id":"3355","owners":[18],"pid":{"revision_id":0,"type":"depid","value":"3355"},"status":"published"},"_oai":{"id":"oai:redcross.repo.nii.ac.jp:00003355","sets":["99:64:117"]},"author_link":["8083","6842","96","8084","6664","6663","7396"],"item_10002_biblio_info_7":{"attribute_name":"書誌情報","attribute_value_mlt":[{"bibliographicIssueDates":{"bibliographicIssueDate":"2006-03-01","bibliographicIssueDateType":"Issued"},"bibliographicIssueNumber":"1","bibliographicPageEnd":"11","bibliographicPageStart":"6","bibliographicVolumeNumber":"11","bibliographic_titles":[{"bibliographic_title":"徳島赤十字病院医学雑誌"},{"bibliographic_title":"Tokushima Red Cross Hospital Medical Journal","bibliographic_titleLang":"en"}]}]},"item_10002_description_5":{"attribute_name":"抄録","attribute_value_mlt":[{"subitem_description":"高リスク群骨髄異形成症候群（MDS）は高齢者に多い予後の不良な病型で，可能な場合は造血幹細胞移植が推奨されているが，移植適応がなく強力な化学療法も行いえない症例がほとんどを占めている．低用量Ara-C+M-CSF 療法は安全で侵襲の低い治療として有用性が報告されており，過去に当科で施行した症例について検討した．対象は2000年1月より2004年12月までの期間中，当時FAB分類RAEB, RAEB-T またWHO 分類RAEB Ⅰ, Ⅱと診断した患者で,AML へ移行した症例を含む16例で,Ara-C15mg/m2×2皮下注14日間投与後にM-CSF800万単位14日間点滴静注を行い，1～4クール施行した．平均年齢は65歳．RAEB Ⅰ5例RAEB Ⅱ6例で，AML への移行は5例であった．治療効果はCR2例，PR3例，NR11例で，奏効率31.3％，寛解率12.5％であった．平均生存期間は19.6か月であった．CRの2例は，1例が17か月後に再発したが，32か月後生存中で，1例は38か月後もCRである．PR の3例は1例が9か月後に死亡し，他２例は支持療法を主体に生存中である．NR11例中7例は20か月以内に死亡し，骨髄非破壊的前処置による造血幹細胞移植（RIST）後に寛解した1例を含む4例が生存中であった．本邦における報告とくらべ，寛解率，奏効率ともにやや低かったが，平均生存期間は同様であった．芽球比率や血球減少と治療効果との関連は明らかではなく，予後の不良な染色体異常のある例で効果が乏しかった．NR 例でも血液学的改善効果が得られた例もあり，QOLの改善も期待できる治療であると考えられた．","subitem_description_type":"Abstract"}]},"item_10002_heading_23":{"attribute_name":"見出し","attribute_value_mlt":[{"subitem_heading_banner_headline":"原著","subitem_heading_language":"ja"}]},"item_10002_publisher_8":{"attribute_name":"出版者","attribute_value_mlt":[{"subitem_publisher":"徳島赤十字病院"}]},"item_10002_relation_17":{"attribute_name":"関連サイト","attribute_value_mlt":[{"subitem_relation_name":[{"subitem_relation_name_text":"徳島赤十字病院"}],"subitem_relation_type_id":{}}]},"item_10002_source_id_9":{"attribute_name":"ISSN","attribute_value_mlt":[{"subitem_source_identifier":"1346-9878 ","subitem_source_identifier_type":"ISSN"}]},"item_10002_version_type_20":{"attribute_name":"著者版フラグ","attribute_value_mlt":[{"subitem_version_resource":"http://purl.org/coar/version/c_970fb48d4fbd8a85","subitem_version_type":"VoR"}]},"item_creator":{"attribute_name":"著者","attribute_type":"creator","attribute_value_mlt":[{"creatorNames":[{"creatorName":"尾崎, 敬治"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"後藤, 哲也"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"三木, 浩和"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"一宮, 理子"}],"nameIdentifiers":[{},{}]},{"creatorNames":[{"creatorName":"藤野, 修"}],"nameIdentifiers":[{}]},{"creatorNames":[{"creatorName":"三原, 愛"}],"nameIdentifiers":[{},{}]}]},"item_files":{"attribute_name":"ファイル情報","attribute_type":"file","attribute_value_mlt":[{"accessrole":"open_date","date":[{"dateType":"Available","dateValue":"2013-05-03"}],"displaytype":"simple","filename":"trchmj1101_6-11.pdf","filesize":[{"value":"546.6 kB"}],"format":"application/pdf","licensetype":"license_note","mimetype":"application/pdf","url":{"label":"pdf002135","url":"https://redcross.repo.nii.ac.jp/record/3355/files/trchmj1101_6-11.pdf"},"version_id":"89ffe7ba-151c-4dd7-806b-cc6cba1a34a4"}]},"item_keyword":{"attribute_name":"キーワード","attribute_value_mlt":[{"subitem_subject":"骨髄異形成症候群","subitem_subject_scheme":"Other"},{"subitem_subject":"急性骨髄性白血病","subitem_subject_scheme":"Other"},{"subitem_subject":"シタラビン","subitem_subject_scheme":"Other"},{"subitem_subject":"マクロファージコロニー刺激因子(M‐CSF)","subitem_subject_scheme":"Other"},{"subitem_subject":"myelodysplastic syndrome","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"acute myelogenous leukemia","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"cytosine arabinoside","subitem_subject_language":"en","subitem_subject_scheme":"Other"},{"subitem_subject":"macrophage colonystimul atingfactor(M-CSF)","subitem_subject_language":"en","subitem_subject_scheme":"Other"}]},"item_language":{"attribute_name":"言語","attribute_value_mlt":[{"subitem_language":"jpn"}]},"item_resource_type":{"attribute_name":"資源タイプ","attribute_value_mlt":[{"resourcetype":"departmental bulletin paper","resourceuri":"http://purl.org/coar/resource_type/c_6501"}]},"item_title":"高リスク群骨髄異形成症候群(MDS)に対する低用量Ara‐C+M‐CSF療法の検討","item_titles":{"attribute_name":"タイトル","attribute_value_mlt":[{"subitem_title":"高リスク群骨髄異形成症候群(MDS)に対する低用量Ara‐C+M‐CSF療法の検討"},{"subitem_title":"Treatment with Low-dose Ara-C Followed by Administration of Macrophage Colony-Stimulating Factor in Patients with High-risk Groups of Myelodysplastic Syndrome and its Leukemic Phase.","subitem_title_language":"en"}]},"item_type_id":"10002","owner":"18","path":["117"],"pubdate":{"attribute_name":"公開日","attribute_value":"2013-05-03"},"publish_date":"2013-05-03","publish_status":"0","recid":"3355","relation_version_is_last":true,"title":["高リスク群骨髄異形成症候群(MDS)に対する低用量Ara‐C+M‐CSF療法の検討"],"weko_creator_id":"18","weko_shared_id":18},"updated":"2023-06-20T22:02:31.204001+00:00"}